Response to catecholamine stimulation of polymorphisms of the beta-1 and beta-2 adrenergic receptors

Rhondalyn C. McLean, Stacy W. Baird, Lewis C. Becker, Susan N. Townsend, Gary Gerstenblith, David A. Kass, Gordon F. Tomaselli, Steven P. Schulman

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Previous studies have demonstrated that β-adrenergic receptor polymorphisms affect outcomes in patients with heart failure or after an acute coronary syndrome. Whether β-adrenergic polymorphisms influence catecholamine responses in patients with cardiovascular disease is not known. Cardiovascular responses to the β1-receptor agonist dobutamine and the β2-receptor agonist terbutaline were studied using gated blood pool scintigraphy in 21 patients on long-term β-blocker therapy. Heart rate (HR), stroke volume (SV), and cardiac output (CO) increased, and end-systolic volume decreased with dobutamine and terbutaline. Changes in HR and CO with dobutamine were higher for those with <1 β1 Arg389 allele than those homozygous for the Gly389 allele (change in HR 15 vs 1 beat/min, p = 0.02; change in CO 2.4 vs 1.0 L/min, p = 0.02). Increases in HR, CO, and SV with terbutaline were greater for those homozygous for the β2 Glu27 allele than those with <1 Gln27 allele (change in HR 13.7 vs 4.8 beats/min, p = 0.048; change in CO 3.1 vs 1.6 L/min, p = 0.034; change in SV 28.3 vs 14.8 ml, p = 0.045). Changes in CO and volume with terbutaline were greater in those with an ejection fraction <40% than in those with an ejection fraction <40%. In conclusion, β-receptor gene variants significantly influence inotropic and chronotropic responses to β-agonist exposure in patients on β-blocker therapy.

Original languageEnglish (US)
Pages (from-to)1001-1007
Number of pages7
JournalAmerican Journal of Cardiology
Volume110
Issue number7
DOIs
StatePublished - Oct 1 2012
Externally publishedYes

Fingerprint

Adrenergic beta-2 Receptors
Cardiac Output
Catecholamines
Terbutaline
Heart Rate
Dobutamine
Alleles
Stroke Volume
Cardiac Volume
Gated Blood-Pool Imaging
Acute Coronary Syndrome
Adrenergic Agents
Adrenergic Receptors
Cardiovascular Diseases
Heart Failure
Therapeutics
Genes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

McLean, R. C., Baird, S. W., Becker, L. C., Townsend, S. N., Gerstenblith, G., Kass, D. A., ... Schulman, S. P. (2012). Response to catecholamine stimulation of polymorphisms of the beta-1 and beta-2 adrenergic receptors. American Journal of Cardiology, 110(7), 1001-1007. https://doi.org/10.1016/j.amjcard.2012.05.029

Response to catecholamine stimulation of polymorphisms of the beta-1 and beta-2 adrenergic receptors. / McLean, Rhondalyn C.; Baird, Stacy W.; Becker, Lewis C.; Townsend, Susan N.; Gerstenblith, Gary; Kass, David A.; Tomaselli, Gordon F.; Schulman, Steven P.

In: American Journal of Cardiology, Vol. 110, No. 7, 01.10.2012, p. 1001-1007.

Research output: Contribution to journalArticle

McLean, RC, Baird, SW, Becker, LC, Townsend, SN, Gerstenblith, G, Kass, DA, Tomaselli, GF & Schulman, SP 2012, 'Response to catecholamine stimulation of polymorphisms of the beta-1 and beta-2 adrenergic receptors', American Journal of Cardiology, vol. 110, no. 7, pp. 1001-1007. https://doi.org/10.1016/j.amjcard.2012.05.029
McLean, Rhondalyn C. ; Baird, Stacy W. ; Becker, Lewis C. ; Townsend, Susan N. ; Gerstenblith, Gary ; Kass, David A. ; Tomaselli, Gordon F. ; Schulman, Steven P. / Response to catecholamine stimulation of polymorphisms of the beta-1 and beta-2 adrenergic receptors. In: American Journal of Cardiology. 2012 ; Vol. 110, No. 7. pp. 1001-1007.
@article{8d68e1f19f3542ef8bb4fa85428837c6,
title = "Response to catecholamine stimulation of polymorphisms of the beta-1 and beta-2 adrenergic receptors",
abstract = "Previous studies have demonstrated that β-adrenergic receptor polymorphisms affect outcomes in patients with heart failure or after an acute coronary syndrome. Whether β-adrenergic polymorphisms influence catecholamine responses in patients with cardiovascular disease is not known. Cardiovascular responses to the β1-receptor agonist dobutamine and the β2-receptor agonist terbutaline were studied using gated blood pool scintigraphy in 21 patients on long-term β-blocker therapy. Heart rate (HR), stroke volume (SV), and cardiac output (CO) increased, and end-systolic volume decreased with dobutamine and terbutaline. Changes in HR and CO with dobutamine were higher for those with <1 β1 Arg389 allele than those homozygous for the Gly389 allele (change in HR 15 vs 1 beat/min, p = 0.02; change in CO 2.4 vs 1.0 L/min, p = 0.02). Increases in HR, CO, and SV with terbutaline were greater for those homozygous for the β2 Glu27 allele than those with <1 Gln27 allele (change in HR 13.7 vs 4.8 beats/min, p = 0.048; change in CO 3.1 vs 1.6 L/min, p = 0.034; change in SV 28.3 vs 14.8 ml, p = 0.045). Changes in CO and volume with terbutaline were greater in those with an ejection fraction <40{\%} than in those with an ejection fraction <40{\%}. In conclusion, β-receptor gene variants significantly influence inotropic and chronotropic responses to β-agonist exposure in patients on β-blocker therapy.",
author = "McLean, {Rhondalyn C.} and Baird, {Stacy W.} and Becker, {Lewis C.} and Townsend, {Susan N.} and Gary Gerstenblith and Kass, {David A.} and Tomaselli, {Gordon F.} and Schulman, {Steven P.}",
year = "2012",
month = "10",
day = "1",
doi = "10.1016/j.amjcard.2012.05.029",
language = "English (US)",
volume = "110",
pages = "1001--1007",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Response to catecholamine stimulation of polymorphisms of the beta-1 and beta-2 adrenergic receptors

AU - McLean, Rhondalyn C.

AU - Baird, Stacy W.

AU - Becker, Lewis C.

AU - Townsend, Susan N.

AU - Gerstenblith, Gary

AU - Kass, David A.

AU - Tomaselli, Gordon F.

AU - Schulman, Steven P.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Previous studies have demonstrated that β-adrenergic receptor polymorphisms affect outcomes in patients with heart failure or after an acute coronary syndrome. Whether β-adrenergic polymorphisms influence catecholamine responses in patients with cardiovascular disease is not known. Cardiovascular responses to the β1-receptor agonist dobutamine and the β2-receptor agonist terbutaline were studied using gated blood pool scintigraphy in 21 patients on long-term β-blocker therapy. Heart rate (HR), stroke volume (SV), and cardiac output (CO) increased, and end-systolic volume decreased with dobutamine and terbutaline. Changes in HR and CO with dobutamine were higher for those with <1 β1 Arg389 allele than those homozygous for the Gly389 allele (change in HR 15 vs 1 beat/min, p = 0.02; change in CO 2.4 vs 1.0 L/min, p = 0.02). Increases in HR, CO, and SV with terbutaline were greater for those homozygous for the β2 Glu27 allele than those with <1 Gln27 allele (change in HR 13.7 vs 4.8 beats/min, p = 0.048; change in CO 3.1 vs 1.6 L/min, p = 0.034; change in SV 28.3 vs 14.8 ml, p = 0.045). Changes in CO and volume with terbutaline were greater in those with an ejection fraction <40% than in those with an ejection fraction <40%. In conclusion, β-receptor gene variants significantly influence inotropic and chronotropic responses to β-agonist exposure in patients on β-blocker therapy.

AB - Previous studies have demonstrated that β-adrenergic receptor polymorphisms affect outcomes in patients with heart failure or after an acute coronary syndrome. Whether β-adrenergic polymorphisms influence catecholamine responses in patients with cardiovascular disease is not known. Cardiovascular responses to the β1-receptor agonist dobutamine and the β2-receptor agonist terbutaline were studied using gated blood pool scintigraphy in 21 patients on long-term β-blocker therapy. Heart rate (HR), stroke volume (SV), and cardiac output (CO) increased, and end-systolic volume decreased with dobutamine and terbutaline. Changes in HR and CO with dobutamine were higher for those with <1 β1 Arg389 allele than those homozygous for the Gly389 allele (change in HR 15 vs 1 beat/min, p = 0.02; change in CO 2.4 vs 1.0 L/min, p = 0.02). Increases in HR, CO, and SV with terbutaline were greater for those homozygous for the β2 Glu27 allele than those with <1 Gln27 allele (change in HR 13.7 vs 4.8 beats/min, p = 0.048; change in CO 3.1 vs 1.6 L/min, p = 0.034; change in SV 28.3 vs 14.8 ml, p = 0.045). Changes in CO and volume with terbutaline were greater in those with an ejection fraction <40% than in those with an ejection fraction <40%. In conclusion, β-receptor gene variants significantly influence inotropic and chronotropic responses to β-agonist exposure in patients on β-blocker therapy.

UR - http://www.scopus.com/inward/record.url?scp=84866114040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866114040&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2012.05.029

DO - 10.1016/j.amjcard.2012.05.029

M3 - Article

VL - 110

SP - 1001

EP - 1007

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -